NCT02126579 2024-02-28
MEL60
University of Virginia
Phase 1/2 Completed
Clinical Trials
3 trialsNCT00874861 2015-12-08
HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas
University of Pittsburgh
Phase EARLY_PHASE1 Completed
NCT00162500 2010-11-10
A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies
Hadassah Medical Organization
Phase 2 Withdrawn